Evaluation of Pharmacological Activity of Heterobimetallic Coordination Compounds Containing N, N-Bis (2-hydroxyethyl)-Ethylenediamine on HT29, HeLa, C6 and Vero cells

Document Type : Research article


1 aculty of Art and Science, Department of Molecular Biology and Genetics, Gaziosmanpaşa University, 60240, Tokat, Turkey

2 Faculty of Engineering, Department of Bioengineering, Munzur University, 62000, Tunceli, Turkey.


The present study was conducted in order to investigate the pharmacological activities of three heterobimetallic coordination compounds: [Cd(N-bishydeten)2][Ni(CN)4] (C1), [Cu2(N-bishydeten)2Co(CN)6].3H2O (C2), and K[Cd(N-bishydeten)Co(CN)6].1.5H2O (C3) (N-bishydeten = N,N-bis(2-hydroxyethyl)-ethylenediamine). This paper describes the ability of complexes to inhibit cell growth, cell migration and human topoisomerase I and to interact with DNA/BSA; this paper also evaluates the potential mechanisms of action exhibited by these compounds via the use of TUNEL, IHC, DNA fragmentation and restriction endonuclease inhibitor activity techniques. Studies on HT29, HeLa, C6 and Vero cells revealed that each compound demonstrated significant antiproliferative activity in conjunction with regressed cell migration velocity and caused apoptotic changes in cell surface morphology such as cell rounding, membrane blebbing and blistering followed by DNA fragmentations. There is strong data to suggest that the mechanisms of action exhibited by these compounds are associated with their DNA/BSA binding features. The IC50 and binding constant range for the compounds are 20-180 µM and 1.2-3.2 x 104 M-1, respectively. Moreover, we observed that these compounds alter the P53-Bcl-2 ratio, indicating differentiation in cellular fate leading to cell death. Furthermore, they also inhibit the relaxation activity of human topoisomerase I which regulates the topological states of the DNA and inhibit KpnI or BamHI restriction endonucleases. Both effects of these compounds may be used in combination with adjuvant therapy for cancer. In conclusion, preliminary information demonstrates that these compounds have found to exhibit effective antiproliferative activity against cancer cell lines, indicating that they are a potent candidate for further pharmacological studies.


Main Subjects

World Cancer Report, 2015; (Accessed March 15,
2016). Available from: URL: http://www.iarc.fr/en/
publications /books/wcr/wcr-order.php.
Vignesh G, Senthilkumar R, Paul P, Periasamy VS,
Akbarsha MA and Arunachalam S. Protein binding
and biological evaluation of a polymer-anchored
cobalt (III) complex containing a 2,20-bipyridine
ligand. RSC Adv. (2014) 4: 57483-92.
Samie N, Haerian BS, Muniandy S, Marlina A,
Kanthimathi MS, Abdullah NB, Ahmadian G and
Aziddin RER. Mechanism of Action of the Novel
Nickel (II) Complex in Simultaneous Reactivation
of the Apoptotic Signaling Networks Against Human
Colon Cancer Cells. Front. Pharmacol. (2016) 6: 313.
Qi J, Zhang Y, Gou Y, Zhang Z, Zhou Z, Wu X, Yang
F and Liang H. Developing an Anticancer Copper(II)
Pro-Drug Based on the His242 Residue of the Human
Serum Albumin Carrier IIA Subdomain. Mol. Pharm.
(2016) 13: 1501-7 .
Aydın A, Korkmaz N, Tekin Ş and Karadağ A.
Anticancer activities and mechanism of action of
2 novel metal complexes, C16H34N8
Cd and
Ni. Turk J. Biol. (2014) 38: 948-55.
Korkmaz N, Karadağ A, Aydın A, Yanar Y, Karaman
İ and Tekin Ş. Synthesis and characterization of two
novel dicyanidoargentate(I) complexes containing
N-(2-hydroxyethyl)ethylenediamine exhibiting
significant biological activity. New J. Chem. (2014)
38: 4760-73.
Tekin S, Aydın A, Dede S and Karadağ A. Antiproliferative activity of a new coordination compound
containing AuI
 in some cancer cell lines. J.
Biotechnol. (2014) 185: 28-9.
Aydın A, Karadağ A, Tekin Ş, Korkmaz N and Özdemir
A. Two new coordination polymers containing
dicyanidoargentate(I) and dicyanidoaurate(I):
synthesis and characterization, and a detailed in-vitro
investigation of their anticancer activities on some
cancer cell lines. Turk. J. Chem. (2015) 39: 532-49
Karadağ A, Aydın A, Özdemir A and Tekin Ş.
Antiproliferative and cytotoxic activities of a new
cyanido coordination compound on several cancer cell
lines. J. Biotechnol. (2014) 185: 105.
Gielen M and Tiekink ERT. Metallotherapeutic Drugs
and Metal-Based Diagnostic Agents: The Use of
Metals in Medicine. John Wiley & Sons press, 644 p,
West Sussex (2005) 1-560.
Avendano C and Menéndez JC. Medicinal Chemistry
Of Anticancer Drugs. Elsevier science press, 1st
edition, 400 p, Amsterdam (2008) 1-429.
Dabrowiak JC. Metals in Medicine. John Wiley &
Sons, 1st Edition, 321 p, West Sussex (2009) 1-310.
Karadağ A, Aydın A, Dede S, Tekin Ş, Yanar Y,
Çadırcı BH, Soylu MS and Andaç Ö. Five Novel
Dicyanidoaurate(I)-Based Complexes Exhibiting
Significant Biological activities: Synthesis,
Characterization and Three Crystal Structures. New J.
Chem. (2015) 39: 8136-52.
Karadağ A, Aslan Korkmaz Ş, Andaç Ö, Yerli Y
and Topcu Y. Cyano-complexes and salts with
tetracyanonickellateII and N,N-bis(2-hydroxyethyl)-
ethylenediamine: synthesis, IR spectra, magnetic
properties, thermal analyses, and crystal structures. J.
Coord. Chem. (2012) 65: 1685-99.
Aslan Korkmaz Ş, Karadağ A, Korkmaz N, Andaç Ö,
Gürbüz N, Özdemir İ and Topkaya R. Five complexes
containing N,N-bis(2-hydroxyethyl)-ethylenediamine
with tetracyanidopalladate(II): synthesis, crystal
structures, thermal, magnetic, and catalytic properties.
J. Coord. Chem. (2013) 66: 3072-91.
Aslan Korkmaz Ş, Karadağ A, Yerli Y and Soylu
MS. Synthesis and characterization of new
heterometallic cyanido complexes based on
]3- building blocks: crystal structure of
O having a strong
Pharmacological capacity of some heterobimetallics
antiferromagnetic exchange. New J. Chem. (2014) 38:
Porstmann T, Ternynck T and Avrameas S. Quantitation
of 5-bromo-2-deoxyuridine incorporation into DNA:
an enzyme immunoassay for the assessment of the
lymphoid cell proliferative response. J. Immunol.
Methods (1985) 82(1): 169-179.
Sgonc R, Boeck G, Dietrich H, Gruber J, Recheis
H and Wick G. Simultaneous determination of cell
surface antigens and apoptosis. Trends Genet. (1994)
10: 41-2.
Gong J, Traganos F and Darzynkiewicz Z. A selective
procedure for DNA extraction from apoptotic cells
applicable for gel electrophoresis and flow cytometry.
Anal. Biochem. (1994) 218: 314-9..
Chen P-S, Shih Y-W, Huang H-C and Cheng H-W.
Diosgenin, a Steroidal Saponin, Inhibits Migration
and Invasion of Human Prostate Cancer PC-3 Cells
by Reducing Matrix Metalloproteinases Expression.
PLoS ONE (2011) 6: e20164.
Park HJ, Lee HJ, Lee E-J, Hwang HJ, Shin S-H,
Suh M-E, Kim C, Kim HJ, Seo E-K and Lee SK.
Cytotoxicity and DNA Topoisomerase Inhibitory
Activity of Benz[f]indole-4,9-dione Analogs. Biosci.
Biotechnol. Biochem. (2003) 67: 1944-9.
Catanzaro JM, Sheshadri N, Pan J-A, Sun Y, Shi C, Li
J, Powers RS, Crawford HC and Zong W-X. Oncogenic
Ras induces inflammatory cytokine production by
up-regulating the squamous cell carcinoma antigens
SerpinB3/B4. Nat. Commun. (2014) 5: 3729.
Wolfe A, Shimer GH and Meehan T. Polycyclic
aromatic hydrocarbons physically intercalate into
duplex regions of denatured DNA. Biochemistry
(1987) 26: 6392-6.
Lakowicz JR and Weber G. Quenching of fluorescence
by oxygen. A probe for structural fluctuations in
macromolecules. Biochemistry (1973) 12: 4161-70.
Sirajuddin M, Ali S and Badshah A. Drug–DNA
interactions and their study by UV–Visible,
fluorescence spectroscopies and cyclic voltammetry.
J. Photochem. Photobiol. B (2013) 124: 1-19.
Kapdi AR and Fairlamb IJS. Anti-cancer palladium
complexes: a focus on PdX2
, palladacycles and
related complexes. Chem. Soc. Rev. (2014) 43: 4751.
Munteanu CR and Suntharalingam K. Advances in
cobalt complexes as anticancer agents. Dalton Trans.
(2015) 44: 13796. 10.
Gao E, Lin L, Liu L, Zhu M, Wang B and Gao
X. Two new palladium(II) complexes: synthesis,
characterization and their interaction with HeLa cells.
Dalton Trans. (2012) 41: 11187-94
Tanaka M, Kataoka H, Yano S, Ohi H, Kawamoto K,
Shibahara T, Mizoshita T, Mori Y, Tanida S, Kamiya
T and Joh T. Anti-cancer effects of newly developed
chemotherapeutic agent, glycoconjugated palladium
(II) complex, against cisplatin-resistant gastric cancer
cells. BMC Cancer (2013) 13: 237.
Tsekova D, Gorolomova P, Gochev G, Skumryevb
V, Momekov G, Momekova D and Gencheva G.
Synthesis, structure and in-vitro cytotoxic studies of
novel paramagnetic palladium(III) complexes with
hematoporphyrin IX. J. Inorg. Biochem. (2013) 124:
Keter FK, Kanyanda S, Lyantagaye SSL, Darkwa
J, Rees DJG and Meyer M. In-vitro evaluation of
dichloro-bis(pyrazole)palladium(II) and dichlorobis(pyrazole)platinum(II) complexes as anticancer
agents. Cancer Chemother. Pharmacol. (2008) 63:
Narla RK, Chen C-L, Dong Y and Uckun FM.
In-vivo Antitumor Activity of Bis(4,7-dimethyl-1,10-
phenanthroline) Sulfatooxovanadium(IV) {METVAN
]}. Clin. Cancer Res. (2001) 7:
Beshir AB, Guchhait SK, Gascón JA and Fenteany G.
Synthesis and structure-activity relationships of metalligand complexes that potently inhibit cell migration.
Bioorg. Med. Chem. Lett. (2008) 18: 498-504.
Nazarov AA, Baquié M, Nowak-Sliwinska P, Zava O,
van Beijnum JR, Groessl M, Chisholm DM, Ahmadi
Z, McIndoe JS, Griffioen AW, van den Bergh H and
Dyson PJ. Synthesis and characterization of a new
class of anti-angiogenic agents based on ruthenium
clusters. Sci. Rep. (2013) 3: 1485.
Ahmad M, Afzal M, Tabassum S, Kalińska B,
Mrozinski J and Bharadwaj PK. Synthesis and structure
elucidation of a cobalt(II) complex as topoisomerase I
inhibitor: In-vitro DNA binding, nuclease and RBC
hemolysis. Eur. J. Med. Chem. (2014) 74: 683-93.
Chew ST, Lo KM, Lee SK, Heng MP, Teoh WY, Sim
KS and Tan KW. Copper complexes with phosphonium
containing hydrazone ligand: Topoisomerase inhibition
and cytotoxicity study. Eur. J. Med. Chem. (2014) 76:
Pages BJ, Ang DL, Wright EP and Aldrich-Wright JR.
Metal complex interactions with DNA. Dalton Trans.
(2015) 44: 3505-26.